{
    "ticker": "CPRX",
    "name": "Catalyst Pharmaceuticals, Inc.",
    "description": "Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare neurological diseases and disorders. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst aims to address the unmet medical needs of patients with conditions such as Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). The company\u2019s lead product, Firdapse (amifampridine), is the first approved treatment for LEMS in the United States and has demonstrated significant efficacy in increasing muscle strength and function. Catalyst is dedicated to advancing its pipeline of therapies that target rare diseases, leveraging its expertise in clinical development and regulatory affairs to bring important treatments to market. With a strong commitment to patient advocacy, Catalyst actively collaborates with healthcare professionals and organizations to enhance awareness and improve access to care for individuals with rare diseases. The company\u2019s mission is to transform the lives of patients through the development of innovative therapies that provide meaningful benefits.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Coral Gables, Florida, USA",
    "founded": "2002",
    "website": "https://www.catalystpharma.com",
    "ceo": "Patrick J. McEnany",
    "social_media": {
        "twitter": "https://twitter.com/CatalystPharma",
        "linkedin": "https://www.linkedin.com/company/catalyst-pharmaceuticals/"
    },
    "investor_relations": "https://investors.catalystpharma.com",
    "key_executives": [
        {
            "name": "Patrick J. McEnany",
            "position": "CEO"
        },
        {
            "name": "Steven A. Miller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Firdapse"
            ]
        }
    ],
    "seo": {
        "meta_title": "Catalyst Pharmaceuticals, Inc. | Innovative Treatments for Rare Diseases",
        "meta_description": "Catalyst Pharmaceuticals, Inc. is dedicated to developing innovative treatments for rare neurological diseases, including LEMS. Discover our mission and products.",
        "keywords": [
            "Catalyst Pharmaceuticals",
            "Firdapse",
            "LEMS",
            "Rare Diseases",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Catalyst Pharmaceuticals known for?",
            "answer": "Catalyst Pharmaceuticals is known for developing treatments for rare neurological diseases, particularly its product Firdapse for LEMS."
        },
        {
            "question": "Who is the CEO of Catalyst Pharmaceuticals?",
            "answer": "Patrick J. McEnany is the CEO of Catalyst Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Catalyst Pharmaceuticals headquartered?",
            "answer": "Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida, USA."
        },
        {
            "question": "What is Firdapse?",
            "answer": "Firdapse is the first approved treatment for Lambert-Eaton myasthenic syndrome (LEMS) in the United States."
        },
        {
            "question": "When was Catalyst Pharmaceuticals founded?",
            "answer": "Catalyst Pharmaceuticals was founded in 2002."
        }
    ],
    "competitors": [
        "ALNY",
        "SRPT",
        "RARE",
        "AVXL"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "VRTX"
    ]
}